Direct isolation of recombinant human antibodies against group B Neisseria meningitidis from scFv expression libraries - PubMed

Direct isolation of recombinant human antibodies against group B Neisseria meningitidis from scFv expression libraries

John Erik Stacy et al. J Immunol Methods. 2003 Dec.

Abstract

The successful generation of human antibodies from large nai;ve antibody libraries requires iterative selection steps. Here, we describe a new and fast method for the isolation of high affinity antibodies directly from human single chain Fv antibody (scFv) expression libraries. Escherichia coli scFv expression libraries were made from peripheral blood lymphocytes from four individuals vaccinated with group B Neisseria meningitidis outer membrane vesicle (OMV) vaccine. Forty thousand clones were directly screened for antibodies binding N. meningitidis strain 44/76 (B:15:P1.7,16). Of 430 specific clones detected, 225 candidates were isolated and re-screened against the N. meningitidis strains NZ-98/254 (B:4:P1.7b,4) giving 4% cross-reactive clones. Antibodies were further characterized by DNA sequencing, ELISA and surface plasmon resonance (SPR) analysis, showing broad V-gene diversity and nanomolar scFv affinities. Antibodies derived by this method may assist in the discovery and development of new vaccine antigens as well as therapeutic antibody agents for the treatment of meningococcal diseases.

Similar articles

• The role of valency in the selection of anti-carbohydrate single-chain Fvs from phage display libraries.

  MacKenzie R, To R. MacKenzie R, et al. J Immunol Methods. 1998 Nov 1;220(1-2):39-49. doi: 10.1016/s0022-1759(98)00143-4. J Immunol Methods. 1998. PMID: 9839924

• Selection of human single chain Fv antibody fragments binding and inhibiting Helicobacter pylori urease.

  Houimel M, Corthesy-Theulaz I, Fisch I, Wong C, Corthesy B, Mach J, Finnern R. Houimel M, et al. Tumour Biol. 2001 Jan-Feb;22(1):36-44. doi: 10.1159/000030153. Tumour Biol. 2001. PMID: 11054025

• Characterization of Escherichia coli K1 colominic acid-specific murine antibodies that are cross-protective against Neisseria meningitidis groups B, C, and Y.

  Park IH, Lin J, Choi JE, Shin JS. Park IH, et al. Mol Immunol. 2014 Jun;59(2):142-53. doi: 10.1016/j.molimm.2014.01.016. Epub 2014 Mar 4. Mol Immunol. 2014. PMID: 24603121

• A deeper mining on the protein composition of VA-MENGOC-BC®: An OMV-based vaccine against N. meningitidis serogroup B and C.

  Masforrol Y, Gil J, García D, Noda J, Ramos Y, Betancourt L, Guirola O, González S, Acevedo B, Besada V, Reyes O, González LJ. Masforrol Y, et al. Hum Vaccin Immunother. 2017 Nov 2;13(11):2548-2560. doi: 10.1080/21645515.2017.1356961. Epub 2017 Oct 30. Hum Vaccin Immunother. 2017. PMID: 29083947 Free PMC article. Review.

• Obtention and engineering of non-human primate (NHP) antibodies for therapeutics.

  Pelat T, Hust M, Thullier P. Pelat T, et al. Mini Rev Med Chem. 2009 Dec;9(14):1633-8. doi: 10.2174/138955709791012283. Mini Rev Med Chem. 2009. PMID: 20105119 Review.

Cited by

• Development and implementation of a single-chain Fv antibody for specific detection of Bacillus anthracis spores.

  Mechaly A, Zahavy E, Fisher M. Mechaly A, et al. Appl Environ Microbiol. 2008 Feb;74(3):818-22. doi: 10.1128/AEM.01244-07. Epub 2007 Oct 26. Appl Environ Microbiol. 2008. PMID: 17965209 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database